MULTIPLE SCLEROSIS THERAPY AND DIAGNOSIS

Use of a compound capable of reducing the activity of Core 2 GlcNAc-T in the manufacture of a medicament for the treatment of Multiple Sclerosis is disclosed. Also disclosed is a method of diagnosing Multiple Sclerosis in a subject and a method of determining the utility of a test substance for use...

Full description

Saved in:
Bibliographic Details
Main Authors HAGAN, RUSSELL, CHIBBER, RAKESH
Format Patent
LanguageEnglish
French
Published 25.08.2015
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS OR TEST PAPERS THEREFOR
CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROCESSES OF PREPARING SUCH COMPOSITIONS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
TESTING
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Use of a compound capable of reducing the activity of Core 2 GlcNAc-T in the manufacture of a medicament for the treatment of Multiple Sclerosis is disclosed. Also disclosed is a method of diagnosing Multiple Sclerosis in a subject and a method of determining the utility of a test substance for use in the treatment of Multiple Sclerosis comprising determining the ability of the substance to inhibit the activity of Core 2 GlcNAc-T.
Bibliography:Application Number: CA20062613210